文献速递白血病

多中心11年经验:急性髓系白血病减强度与强化疗的比较

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.
PubMed 文献 · Blood · 2021-01-01

该研究基于多中心回顾性队列(n=1292,2008-2012年,6家机构)和前瞻性队列(n=695,2013-2017年,13家机构),使用AML复合模型(AML-CM)比较减强度与强化诱导治疗在急性髓系白血病(AML)中的结局。回顾性队列中减强度治疗与AML-CM评分4-6、7-9和≥10的更高死亡风险相关;前瞻性队列中调整年龄、医生评估的KPS和治愈机会后,死亡风险和生活质量相似,但减强度治疗住院时间更短。研究质疑减强度治疗(除缩短住院时间外)的生存和生活质量获益。

要点

  • 减强度治疗与AML-CM评分4-6、7-9和≥10的更高死亡风险相关,独立于异基因移植。
  • 前瞻性队列中调整年龄、KPS和治愈机会后,减强度与强化治疗的死亡风险和生活质量相似。
  • 减强度治疗住院时间更短,但生存和生活质量获益未得到证实。

核心结论

  • 研究质疑减强度治疗在AML患者(包括70-79岁或高合并症负担者)中的生存和生活质量获益,但住院时间更短。
  • 需要随机试验更好地评估减强度与强化治疗或联合治疗的价值。

研究设计与样本

  • 多中心回顾性队列(n=1292),2008-2012年,6家机构。
  • 前瞻性队列(n=695),2013-2017年,13家机构。
  • 使用AML复合模型(AML-CM)分配更高评分给年龄更大、合并症负担增加和不良细胞遗传学风险。

主要发现

  • 回顾性队列中,减强度治疗接受者年龄更大、合并症更多、不良细胞遗传学更多、KPS更差。
  • 减强度治疗与AML-CM评分4-6、7-9和≥10的更高死亡风险相关,独立于异基因移植,且在70-79岁患者中相似。
  • 前瞻性队列中,两组基线生活质量、老年评估和患者结局偏好相似。
  • 减强度治疗后死亡风险更高,但调整年龄、医生分配的KPS和治愈机会后,死亡风险和生活质量相似。
  • 减强度治疗接受者住院时间更短。

关键数值与推荐

  • AML-CM评分分组:4-6、7-9、≥10。
  • 减强度治疗与AML-CM评分4-6、7-9和≥10的更高死亡风险相关。

临床怎么用

  • 对于AML患者,减强度治疗可能不提供生存或生活质量优势(除缩短住院时间外),包括70-79岁或高合并症负担者。
  • 临床决策应综合考虑年龄、合并症、细胞遗传学风险和患者偏好,并期待随机试验证据。

局限性

  • 回顾性队列中减强度治疗接受者基线特征更差,可能存在选择偏倚。
  • 前瞻性队列中调整因素后结果相似,但需随机试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Less-intensive induction therapies are increasingly used in older patients with acute myeloid leukemia (AML). Using an AML composite model (AML-CM) assigning higher scores to older age, increased comorbidity burdens, and adverse cytogenetic risks, we defined 3 distinct prognostic groups and compared outcomes after less-intensive vs intensive induction therapies in a multicenter retrospective cohort (n = 1292) treated at 6 institutions from 2008 to 2012 and a prospective cohort (n = 695) treated at 13 institutions from 2013 to 2017. Prospective study included impacts of Karnofsky performance status (KPS), quality of life (QOL), and physician perception of cure. In the retrospective cohort, recipients of less-intensive therapies were older and had more comorbidities, more adverse cytogenetics, and worse KPS. Less-intensive therapies were associated with higher risks of mortality in AML-CM scores of 4 to 6, 7 to 9, and ≥10. Results were independent of allogeneic transplantation and similar in those age 70 to 79 years. In the prospective cohort, the 2 groups were similar in baseline QOL, geriatric assessment, and patient outcome preferences. Higher mortality risks were seen after less-intensive therapies. However, in models adjusted for age, physician-assigned KPS, and chance of cure, mortality risks and QOL were similar. Less-intensive therapy recipients had shorter length of hospitalization (LOH). Our study questions the survival and QOL benefits (except LOH) of less-intensive therapies in patients with AML, including those age 70 to 79 years or with high comorbidity burdens. A randomized trial in older/medically infirm patients is required to better assess the value of less-intensive and intensive therapies or their combination. This trial was registered at www.clinicaltrials.gov as #NCT01929408.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sorror ML, Storer BE, Fathi AT, et al. Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood. 2021. PMID: 34351368. doi:10.1182/blood.2020008812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。